CagriSema
Also known as: cagrisema
CagriSema is Novo Nordisk's investigational once-weekly fixed-dose co-formulation of cagrilintide 2.4 mg (long-acting amylin analog) with semaglutide 2.4 mg (GLP-1 receptor agonist) for chronic weight management. Unlike the other grey-market blends, it has a proper Phase 3 clinical program. Novo Nordisk filed an FDA NDA in December 2025; as of April 2026 it is under FDA review and not yet approved.
Who's worth your money for CagriSema
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (82) of 1 scored sellers
$65.99 · 10mg
Average price
$9.59/mg
Sellers
7
45-day trend
+15.3%
7 of 7 sellers have a current price· 6 stale hidden
- Modern Research Peptides82
✓ verified at source · just now
$6.60/mg -31.2% vs avg$65.99
10mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch CagriSema
Get one email when the market actually moves — no newsletter, no noise.
About CagriSema
CAS
—
Molecular formula
—
Typical dose range
2.4 mg/week cagrilintide + 2.4 mg/week semaglutide, subcutaneous once-weekly; dose-escalation starting at 0.16 mg/week cagrilintide escalated over 16 weeks
Half-life
Cagrilintide ~184 hours (~7.7 days); semaglutide ~158 hours (~6.6 days)
COAs for CagriSema
7 third-party tests across 5 vendors. Each card links to the full report.
For
CagriSema
by Simple Peptide· batch 02-21101-02905-P
For
CagriSema
by Simple Peptide· batch CGSM09032025-J
For
CagriSema
by Profound Aminos· batch 2025-04-31
For
CagriSema
by Hydro Research Peptides· batch 2024-08-05
For
CagriSema
by Profound Aminos· batch cmojb7ss001e3kirxyi4q8sbq
Purity not on file
For
Cagrisema
by Peptide Crafters· batch PC-J2-CS10
Purity not on file
For
Cariintide/Semaglutide
by Certified Peptides· batch 251227CS53
20 citations indexed for CagriSema
review · 2026
New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus
Introduction Type 2 diabetes mellitus (T2DM) and obesity represent two major global health challenges. Amylin-based agonists offer a promising perspective. Three frontrunner agents of this class are increasingly being investigated: zenagamtide, eloralintide and cagrilintide-semaglutide (CagriSema).
Study · 2026
Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis
Background CagriSema combines cagrilintide with semaglutide and may improve glycaemic control and body weight in Type 2 diabetes. We evaluated its dose- and comparator-specific efficacy and safety.
Study · 2026
Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)
Importance Cagrilintide-semaglutide (CagriSema) is a fixed-dose combination of the amylin receptor agonist cagrilintide and the glucagon-like peptide-1 receptor agonist semaglutide administered subcutaneously once weekly.
Study · 2026
Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials
Background Overweight status, obesity, and diabetes represent significant socioeconomic burdens that require long-term management.
meta-analysis · 2026
CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis
Introduction Semaglutide 2.4 mg is the reference pharmacotherapy for weight management, yet many patients do not reach ambitious weight-loss targets. CagriSema, a fixed-dose combination of cagrilintide and semaglutide, may offer additional benefit through complementary mechanisms.
animal · 2026
Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats
Purpose CagriSema (CS), combining the amylin receptor agonist cagrilintide with the glucagon-like peptide 1 receptor agonist semaglutide, is being developed for obesity and type 2 diabetes. We quantified CS effects on energy balance during initial treatment, weight maintenance, and after discontinuation.